共 50 条
- [1] Patisiran, an Investigational RNAi Therapeutic for Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy: Results from the Phase 3 APOLLO studyNEUROLOGY, 2018, 90Adams, DavidGonzalez-Duarte, AlejandraO'Riordan, WilliamYang, Chih-ChaoYamashita, TaroKristen, ArntTournev, IvayloSchmidt, HartmutCoelho, TeresaBerk, John L.Lin, Kon-PingDyck, Peter J.Gandhi, PriteshSweetser, MarianneChen, JihongGoyal, SunitaGollob, JaredSuhr, Ole
- [2] Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathyBMC NEUROLOGY, 2017, 17Adams, DavidSuhr, Ole B.Dyck, Peter J.Litchy, William J.Leahy, Raina G.Chen, JihongGollob, JaredCoelho, Teresa
- [3] Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathyBMC Neurology, 17David AdamsOle B. SuhrPeter J. DyckWilliam J. LitchyRaina G. LeahyJihong ChenJared GollobTeresa Coelho
- [4] EVALUATING THE BUDGET IMPACT OF PATISIRAN, THE FIRST APPROVED RNAI THERAPEUTIC, FOR TREATING THE POLYNEUROPATHY OF HATTR AMYLOIDOSISVALUE IN HEALTH, 2019, 22 : S50 - S50Lin, H.Merkel, M.Pelligra, C.Shah, A.
- [5] Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisJOURNAL OF NEUROLOGY, 2020, 267 (03) : 703 - 712Gonzalez-Duarte, AlejandraBerk, John L.Quan, DiannaMauermann, Michelle L.Schmidt, Hartmut H.Polydefkis, MichaelWaddington-Cruz, MarciaUeda, MitsuharuConceicao, Isabel M.Kristen, Arnt V.Coelho, TeresaCauquil, Cecile A.Tard, CelineMerkel, MadelineAldinc, EmreChen, JihongSweetser, Marianne T.Wang, Jing JingAdams, David
- [6] Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisJournal of Neurology, 2020, 267 : 703 - 712Alejandra González-DuarteJohn L. BerkDianna QuanMichelle L. MauermannHartmut H. SchmidtMichael PolydefkisMárcia Waddington-CruzMitsuharu UedaIsabel M. ConceiçãoArnt V. KristenTeresa CoelhoCécile A. CauquilCéline TardMadeline MerkelEmre AldincJihong ChenMarianne T. SweetserJing Jing WangDavid Adams
- [7] Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with PolyneuropathyNEUROLOGY, 2017, 88Adams, DavidCoelho, TeresaConceicao, IsabelCruz, Marcia WaddingtonSchmidt, HartmutBuades, JuanCampistol, JosepPouget, JeanBerk, JohnPolydefkis, MichaelZiyadeh, NourPartisano, AngelaChen, JihongGollob, JaredSuhr, Ole
- [8] Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO StudyNEUROLOGY, 2018, 90Adams, DavidGonzalez-Duarte, AlejandraO'Riordan, WilliamYang, Chih-ChaoYamashita, TaroKristen, ArntTournev, IvayloSchmidt, HartmutCoelho, TeresaBerk, John L.Lin, Kong-PingDyck, Peter J.Gandhi, PriteshSweetser, MarianneChen, JihongGoyal, SunitaGollob, JaredSuhr, Ole
- [9] PHASE 2 OPEN-LABEL EXTENSION (OLE) STUDY OF PATISIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHYVALUE IN HEALTH, 2017, 20 (05) : A211 - A212Adams, D.Coelho, T.Conceicao, E.Waddington-Cruz, M.Schmidt, H.Buades, J.Campistol, J. M.Pouget, J.Berk, J. L.Polydefkis, M.Ziyadeh, N.Partisano, A. M.Chen, J.Gollob, J.Suhr, O. B.
- [10] Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO studyJOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2024, 123 (09) : 975 - 984Lin, Kon-PingYang, Chih-ChaoLee, Yi-ChungLee, Ming-JenVest, JohnSweetser, Marianne T.White, Matthew T.Badri, PrajaktaHsieh, Sung-TsangChao, Chi-Chao